
Mina Nikanjam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/982311/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86, 102019.	3.4	327
2	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 2020, 11, 4965.	5.8	172
3	Dosing <i>de novo</i> combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget, 2016, 7, 11310-11320.	0.8	50
4	ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nature Communications, 2017, 8, 241.	5.8	44
5	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naÃ ⁻ ve study. Genome Medicine, 2021, 13, 155.	3.6	44
6	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncolmmunology, 2020, 9, 1708065.	2.1	41
7	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist, 2017, 22, 576-584.	1.9	39
8	Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 1339-1348.	1.1	33
9	Dosing targeted and cytotoxic twoâ€drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. International Journal of Cancer, 2016, 139, 2135-2141.	2.3	31
10	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncolmmunology, 2017, 6, e1338997.	2.1	29
11	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Molecular Oncology, 2021, 15, 67-79.	2.1	28
12	Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemotherapy and Pharmacology, 2018, 81, 171-178.	1.1	21
13	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‣1 expression in cancer patients. International Journal of Cancer, 2020, 146, 3087-3097.	2.3	20
14	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. OncoImmunology, 2020, 9, 1710052.	2.1	17
15	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	2.0	14
16	Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology, 2018, 58, 1604-1617.	1.0	11
17	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Research, 2020, 10, 150.	1.1	9
18	Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochemical Pharmacology, 2020, 172, 113742.	2.0	8

Mina Nikanjam

#	Article	IF	CITATIONS
19	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncolmmunology, 2020, 9, 1781997.	2.1	8
20	Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemotherapy and Pharmacology, 2019, 84, 993-1001.	1.1	6
21	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192.	2.3	6
22	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics, 2021, 20, 1072-1079.	1.9	6
23	Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus, 2020, 12, e8967.	0.2	2
24	S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. European Journal of Clinical Pharmacology, 2021, 77, 1349-1356.	0.8	1
25	New Rationales and Designs for Clinical Trials in the Era of Precision Medicine. , 2018, , 30-30.		0
26	Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus, 2018, 10, e3634.	0.2	0
27	Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations , 2022, 5, .		0